UNSPSC 51433301: Cromakalim or levcromakalim

This classification denotes an antihypertensive agent with the molecular formula C16H18N2O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 0G4X367WA3, chemically known as 2h-1-benzopyran-6-carbonitrile, 3,4-dihydro-3-hydroxy-2,2-dimethyl-4-(2-oxo-1-pyrrolidinyl)-, trans-(+-)- but generally known as cromakalim, which bears US NIH Compound Identifier 71191. European Medicines Agency schedules Cromakalim in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06822MIG.

UNSPSC 51433301 Cromakalim or levcromakalim is a Commodity code for a specific pharmaceutical agent, but state and local governments do not currently solicit this ingredient directly under this code. Instead, recent solicitations under or adjacent to this code reflect broader procurement of advanced life support medications, generic multi-source pharmaceuticals, and over-the-counter products purchased by fire rescue departments, state health agencies, and cooperative purchasing alliances to supply clinical and emergency response operations. The work being bought includes sealed-bid procurement of individual medication vials and injections (epinephrine, adenosine, diltiazem, labetalol) for immediate emergency use; cooperative purchasing frameworks for generic pharmaceuticals and OTC products distributed through authorized wholesalers to multiple state and local facilities; and exploratory vendor outreach through requests for information to assess direct-to-manufacturer prescription fulfillment models. Issuing bodies include city purchasing departments (City of Tampa), state health authorities (Texas Health and Human Services Commission), and multistate cooperative purchasing entities (Minnesota Multistate Cooperative Purchasing Alliance or MMCAP). Fire rescue operations and state Medicaid or employee health programs are the primary customer agencies.

Recent geographic activity centers on Texas, Minnesota, and Florida. Representative solicitations include the City of Tampa Fire Rescue's April 2026 IFB for Advanced Life Support Medications (26P00188, due April 8, 2026, estimated value $40,000 with a 5 percent small local business enterprise bid discount), MMCAP's RFP for Generic Multi Source Pharmaceuticals and OTC Products (S1070000015802, due March 26, 2026, serving Minnesota, Oregon, and participating jurisdictions with July 1, 2026 contract effective date), and the Texas Health and Human Services Commission's April 2026 RFI on Direct-to-Manufacturer Prescriptions (HHS0017013) to inform future procurement strategy for state pharmacy benefit programs. The code itself shows limited direct recent activity; the opportunities tagged to it reflect emergency medical supplies and broader pharmaceutical procurement frameworks rather than procurement specifically for cromakalim or levcromakalim as a line item.